Status:

COMPLETED

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Lead Sponsor:

Seoul National University Hospital

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

PHASE3

Brief Summary

Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant...

Detailed Description

Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvan...

Eligibility Criteria

Inclusion

  • \>18 years old or \<75 years old
  • ECOG 0-2
  • biopsy proven adenocarcinoma of the pancreas
  • no history of previous chemotherapy
  • borderline resectable pancreas cancer
  • no distant metastasis
  • WBC at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3, Platelet count at least 125,000/mm3
  • Bilirubin less than 2.5 mg/dL AST less than 5 times upper limit of normal
  • Creatinine no greater than 1.5 times upper limit of normal
  • informed consent

Exclusion

  • history of previous chemotherapy
  • history of radiation at \>25% area of bone marrow
  • stage unspecified, with distant metastasis, recurrent pancreas cancer
  • history of malignant neoplasm (except stage 0 cancer, skin in situ cancer except malignant melanoma). Patients who are NED after 5 years after treatment of malignant neoplasm can be candidate of this study
  • pregnant, breast-feeding patient
  • uncontrolled or active infection
  • uncontrolled cardiopulmonary disease

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2018

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT01458717

Start Date

November 1 2011

End Date

January 1 2018

Last Update

May 2 2018

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Center for Liver Cancer, National Cancer Center

Goyang-si, Gyeonggi-do, South Korea, 410-769

2

Seoul National University Bundang Hospital

Seongnam, South Korea, 463-707

3

Seoul National University Hospital

Seoul, South Korea, 110-744

4

Samsung Medical Center

Seoul, South Korea, 135-710

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | DecenTrialz